BACKGROUND: The epidermal growth factor receptor (EGFR) has been reported to be overexpressed in anaplastic thyroid carcinoma (ATC). In vitro studies have shown that EGFR tyrosine kinase inhibitors (TKIs) greatly inhibit cellular growth and induced apoptosis in the ATC cell lines, while somatic mutations in the tyrosine kinase domain or an increased gene copy number are associated with increased sensitivity to TKIs in non-small cell lung cancer. AIM: To investigate the prevalence of EGFR overexpression, gene amplification and activating mutation in the tyrosine kinase domain in patients with ATC. METHODS: The EGFR gene status and protein expression were investigated by direct DNA sequencing of the hot-spot regions in exons 18, 19 and 21, fluorescence in situ hybridisation (FISH), and immunohistochemistry in tumour tissues from 23 patients with ATC. RESULTS: On mutational analysis and FISH, neither mutations in the hot-spots nor gene amplification was observed. However, high polysomy was identified in 14/23 (60.9%) patients with ATC. All cases with immunohistochemistry (IHC) positivity (n = 6) had high polysomy, whereas 8/17 (47.1%) cases with IHC negativity had high polysomy (p = 0.048). High polysomy was observed in all 10 cases with giant cell subtype, but in only 4/11 (36.3%) with squamoid and 0/2 with spindle cell sarcomatoid subtype. There was no statistically significant correlation between FISH positivity of ATC tumour and presence of well-differentiated component. CONCLUSION: Despite the low incidence of somatic EGFR gene mutation and amplification in the study samples, in view of the fact that high polysomy was often identified by FISH, as well as the current lack of therapeutic options, EGFR TKIs are worth investigating for treating the patients with ATC who have at least giant cell subtype.
BACKGROUND: The epidermal growth factor receptor (EGFR) has been reported to be overexpressed in anaplastic thyroid carcinoma (ATC). In vitro studies have shown that EGFR tyrosine kinase inhibitors (TKIs) greatly inhibit cellular growth and induced apoptosis in the ATC cell lines, while somatic mutations in the tyrosine kinase domain or an increased gene copy number are associated with increased sensitivity to TKIs in non-small cell lung cancer. AIM: To investigate the prevalence of EGFR overexpression, gene amplification and activating mutation in the tyrosine kinase domain in patients with ATC. METHODS: The EGFR gene status and protein expression were investigated by direct DNA sequencing of the hot-spot regions in exons 18, 19 and 21, fluorescence in situ hybridisation (FISH), and immunohistochemistry in tumour tissues from 23 patients with ATC. RESULTS: On mutational analysis and FISH, neither mutations in the hot-spots nor gene amplification was observed. However, high polysomy was identified in 14/23 (60.9%) patients with ATC. All cases with immunohistochemistry (IHC) positivity (n = 6) had high polysomy, whereas 8/17 (47.1%) cases with IHC negativity had high polysomy (p = 0.048). High polysomy was observed in all 10 cases with giant cell subtype, but in only 4/11 (36.3%) with squamoid and 0/2 with spindle cell sarcomatoid subtype. There was no statistically significant correlation between FISH positivity of ATC tumour and presence of well-differentiated component. CONCLUSION: Despite the low incidence of somatic EGFR gene mutation and amplification in the study samples, in view of the fact that high polysomy was often identified by FISH, as well as the current lack of therapeutic options, EGFR TKIs are worth investigating for treating the patients with ATC who have at least giant cell subtype.
Authors: B McIver; I D Hay; D F Giuffrida; C E Dvorak; C S Grant; G B Thompson; J A van Heerden; J R Goellner Journal: Surgery Date: 2001-12 Impact factor: 3.982
Authors: Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay Journal: JAMA Date: 2003-10-22 Impact factor: 56.272
Authors: Kenneth B Fallon; Cheryl A Palmer; Kevin A Roth; L Burton Nabors; Wenquan Wang; Mark Carpenter; Ruma Banerjee; Peter Forsyth; Keith Rich; Arie Perry Journal: J Neuropathol Exp Neurol Date: 2004-04 Impact factor: 3.685
Authors: Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun Journal: CA Cancer J Clin Date: 2003 Jan-Feb Impact factor: 508.702
Authors: Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Michael V Di Maria; Robert Veve; Roy M Bremmes; Anna E Barón; Chan Zeng; Wilbur A Franklin Journal: J Clin Oncol Date: 2003-09-02 Impact factor: 44.544
Authors: J S Reis-Filho; C Pinheiro; M B K Lambros; F Milanezi; S Carvalho; K Savage; P T Simpson; C Jones; S Swift; A Mackay; R M Reis; J L Hornick; E M Pereira; F Baltazar; C D M Fletcher; A Ashworth; S R Lakhani; F C Schmitt Journal: J Pathol Date: 2006-08 Impact factor: 7.996
Authors: Kevin E Fisher; Jigna C Jani; Sarah B Fisher; Cora Foulks; Charles E Hill; Collin J Weber; Cynthia Cohen; Jyotirmay Sharma Journal: J Surg Res Date: 2013-05-23 Impact factor: 2.192
Authors: Maria K Gule; Yunyun Chen; Daisuke Sano; Mitchell J Frederick; Ge Zhou; Mei Zhao; Zvonimir L Milas; Chad E Galer; Ying C Henderson; Samar A Jasser; David L Schwartz; James A Bankson; Jeffrey N Myers; Stephen Y Lai Journal: Clin Cancer Res Date: 2011-01-10 Impact factor: 12.531
Authors: Michael Ryott; Darawalee Wangsa; Kerstin Heselmeyer-Haddad; Johan Lindholm; Göran Elmberger; Gert Auer; Elisabeth Avall Lundqvist; Thomas Ried; Eva Munck-Wikland Journal: Eur J Cancer Date: 2009-03-28 Impact factor: 9.162
Authors: Youngjoo Lee; Ki Hyeong Lee; Geon Kook Lee; Soo-Hyun Lee; Kun Young Lim; Jungnam Joo; Yun Jung Go; Jin Soo Lee; Ji-Youn Han Journal: Cancer Res Treat Date: 2017-01-13 Impact factor: 4.679
Authors: Seo Yun Kim; Hye-Ryoun Kim; Cheol Hyeon Kim; Jae Soo Koh; Hee Jong Baek; Chang-Min Choi; Joon Seon Song; Jae Cheol Lee; Im Ii Na Journal: Ann Thorac Med Date: 2017 Jan-Mar Impact factor: 2.219